One Year Later

07.09.13 | By

It was one year ago today that the Food and Drug Administration Safety and Innovation Act (FDASIA) was signed into law, reauthorizing the Prescription Drug User Fee Act (PDUFA), permanently reauthorizing the Best

‘Conversations’ Round-Up

07.09.13 | By

Every day, our industry works to develop new medicines that extend and improve the quality of life for patients. As the Baby Boom generation enters retirement age, one critical health care issue that we must address is how to keep our nation’s seniors healthy. It’s a topic that I come across regularly in my role at PhRMA.

Medicines Play an Important Role in Controlling Health Care Costs

07.08.13 | By

Research shows that properly adhering to medications is a major challenge, but patients who take their medications as prescribed are more likely to have better outcomes.

New Insights into Part D Specialty Tier

07.03.13 | By

According to new research by Milliman, a leading actuarial consulting firm, only about 3.3 percent of Part D enrollees filled a prescription for at least one specialty drug in 2011, a very small portion of total Part D enrollment. 

Controlling Non-Communicable Diseases With Our Phones

07.02.13 | By

In the future, we just might be able to control non-communicable diseases with our phones.

An Encounter with Heart Disease

07.02.13 | By

We all know someone impacted by heart disease or stroke. Well that applies to the researchers working on medicines to combat these deadly diseases, as well. Not surprising when you consider that heart disease is the leading cause of death for both men and women, with someone dying from a heart disease related event every minute.

Exploring Health Policy

07.02.13 | By

As we continue to explore health policy through our ‘Conversations’ forum, today we’re introducing the next question and encourage you to weigh in with your thoughts:

“Every day, thousands of Americans turn 65. How do we help ensure that the U.S. system is ready to meet their needs?

PhRMA & BIO Establish Industry PDUFA Tracking Database

07.02.13 | By

As a recent update on implementation of the Prescription Drug User Fee Act (PDUFA) explained, a new review program for new molecular entity (NME) new drug applications (NDA) and original biologic license applications (BLA) was established under

‘Conversations’ Round-Up

07.01.13 | By

Last week, we introduced ‘Conversations,’ a new forum that provides experts, innovators, patients and other stakeholders an opportunity to share ideas through a live, ongoing dialogue about the future of health care.

Getting to the Heart of the Matter

07.01.13 | By

We often discuss in the Catalyst the challenges and promise inherent in the drug discovery process and its impact on patients. And at times talk about how medicines, when used appropriately, can be a valuable part of the solution to controlling health care costs in the U.S.

Pages

Subscribe to RSS - Opinion